July 24, 2018 / 10:40 AM / in 3 months

Biogen quarterly sales rise 9 pct

July 24 (Reuters) - Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza.

Net income attributable to Biogen rose to $866.6 million, or $4.18 per share, in the second quarter ended June 30, from $862.8 million, or $4.07 per share, a year earlier (bit.ly/2LBBu88)

Revenue rose to $3.36 billion from $3.08 billion. (Reporting by Manas Mishra in Bengaluru Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below